Characteristics of erythropoietin antibodies in patients treated with recombinant human erythropoietin

Our aim was to characterize anti-EPO antibodies in serum samples of the patients treated with erythropoietin. 106 serum samples from the patients treated with erythropoietin (EPO) were collected and assayed. 134 serum samples of patients who did not receive EPO were taken for comparative analysis. The anti-EPO antibody detection was performed in ELISA test with rhEPO, by passive capture on ELISA plates, using steptavidin-biotin immunochemical system. Mouse monoclonal antibodies to human IgG, IgG1, IgG2, IgG3 and IgG4 conjugated to horseradish peroxidase were used to detect anti-EPO antibodies, and protein-A peroxidase conjugate was used for quantitative assays. Rabbit anti-human EPO polyclonal antibodies at known concentrations were used as a calibration standard. Six calibration samples at the concentration range of 16-1000 ng/ml were used to plot calibration curves. The lower detection limit was 12 ng/mL, and the quantitative detection limit was 31 ng/ml. Immunochemical capturing led to increasing of total IgG antibody detection by 3.2 times, IgG1 – by 1.1 times IgG2 – by 1.25 times, IgG3 – by 1.5 times, IgG4 – by 1.7 times. Antibodies of mixed isotype were found in most patients. IgG1 or IgG4 antibodies to EPO were determined only in 3 samples. Specific IgM was not detectable among 106 sera samples, whereas total IgG antibodies were detected in 36.8 % of cases. In 34% of sera, their presence was confirmed by detection of at least one of the subclasses. IgG1 antibody was detected in 83.3%; IgG4, in 80.6% of the samples positive for total IgG antibodies. In all cases, IgG2 and/or IgG3 were detected in presence of IgG1 or IgG4 antibodies. The antibody concentration was 3.2 to 35.5 µg/mL in sera from 28 patients, in 8 cases the level of antibodies was > 50 µg/ml, however, being below the limit of quantitative detection in 3 patients. Only 6 samples contained antibodies with avidity index of > 50%. Immunochemical capturing of the antigen led to increased sensitivity for detecting all subclasses of specific antibodies. The specific IgG antibodies to EPO were found in more than 1/3 of serum samples from the patients treated with erythropoietin. Low-avidity antibodies of IgG1 and IgG4 subclasses were determined in most cases.

erythropoietin, antibodies, ELISA, immunogenicity, avidity, human serum

1. Kudryashova A.M., Borisova O.V., Mikhailova N.A., Lonshakov D.V., Katlinsky A.V. Effect of methods of immobilization of erythropoietin on the sensitivity for the detection of specific IgG to EPO in experimental animals sera. Zhurnal mikrobiologii epidemiologii i immunologii = Journal of Microbiology, Epidemiology and Immunobiology, 2017, no. 6, pp. 49-55. (In Russ.)

2. Barger T.E., Kuck A.J., Chirmule N. Swanson S.J., Mytych D.T. Detection of anti-ESA antibodies in human samples from PRCA and non-PRCA patients: an immunoassay platform comparison. Nephrol. Dial. Transplant., 2012, Vol. 27, pp. 688-693.

3. Barger T.E., Wrona D., Goletz T.J. Mytych D.T. A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies. Nephrol. Dial. Transplant., 2012, Vol. 27, no. 10, pp. 3892-3899.

4. Bennett C.L., Luminari S., Nissenson A.R. Tallman M.S., Klinge S.A., McWilliams N., McKoy J.M., Kim B., Lyons E.A., Trifilio S.M., Raisch D.W., Evens A.M., Kuzel T.M., Schumock G.T., Belknap S.M., Locatelli F., Rossert J., Casadevall N. Pure red-cell aplasia and epoetin therapy. N. Engl. J. Med., 2004, Vol. 351, no. 14, pp. 1403-1408.

5. Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrol. Dial. Transplant., 2002, Vol. 17, no. 5, pp. 42-47.

6. Casadevall N., Eckardt K.U., Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J. Am. Soc. Nephrol., 2005, Vol. 16, no.1, pp. 67-69.

7. Casadevall N., Nataf J., Viron B. Kolta A., Kiladjian J.J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., Varet B., Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med., 2002, Vol. 346, no. 7, pp. 469-475.

8. El-Din M., Attia F., Labib S., Omar W. Detection of circulating antierythropoietin antibodies in patients with end stage renal disease on regular hemodialysis. Int. J. Lab. Hematol., 2010, Vol. 32, no. 3, pp. 336-343.

9. Gross J., Moller R., Henke W. Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO. J. Immunol. Methods, 2006, Vol. 313, no. 1-2, pp. 176-182.

10. Guideline on immunogenicity assessment of therapeutic proteins. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP), 2017. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf.

11. Guideline on validation of bioanalytical methods (draft). European Medicines Agency. Committee for Medicinal Products of Human Use (CHMP), 2009. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-validation-bionanalytical-methods_en.pdf.

12. Guideline Validation of analitical procedures (Q2 R1), ICH harmonised tripartite guideline, 2005. Available at: https://database.ich.org/sites/default/files/Q2_R1__Guideline.pdf.

13. Guidance for Industry: Bioanalytical method validation. U.S. Department of Health and Human Services, Food and Drug Administration, 2013. Available at: http://academy.gmp-compliance.org/guidemgr/files/UCM368107.PDF.

14. Herrington W., Wieser C., Rosenkranz A.R. Pure red cell aplasia after treatment of renal anaemia with epoetin theta. Clin. Kidney J., 2013, Vol. 6, no. 5, pp. 539-542.

15. Hoesel W., Gross J., Moller R., Kanne B., Wessner A., Müller G., Müller A., Gromnica-Ihle E., Fromme M., Bischoff S., Haselbeck A. Development and evaluation of a new ELISA for the detection and quantification of antierythropoietin antibodies in human sera. J. Immunol. Methods, 2004, Vol. 294, no. 1-2, pp. 101-110.

16. Macdougall I.C., Casadevall N., Locatelli F., Combe C., London GM., di Paolo S., Kribben A., Fliser D., Messner H., McNeil J., Stevens P., Santoro A., de Francisco A.L., Percheson P., Potamianou A., Foucher A., Fife D., Mérit V., Vercammen E. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol. Dial. Transplant., 2015, Vol. 30, no. 3, pp. 451-460.

17. Macdougall I.C., Roger S.D., de Francisco A., Goldsmith D.J., Schellekens H., Ebbers H., Jelkmann W., London G., Casadevall N., Hörl W.H., Kemeny D.M., Pollock C. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis stimulating agents: new insights. Kidney Int., 2012, Vol. 81, no. 8, pp. 727-732.

18. Nakane P.K., Kawaoi A.J. Peroxidase-labeled antibody. A new method of conjugation. Histochem. Cytochem., 1974, Vol. 22, no. 2, pp. 1084-1091.

19. Öztürk S., Gümüş A., Memili V., Düz M.E., Cebeci E., Koldaş M., Kazancioğlu R. Antierythropoietin Antibodies in hemodialysis patients treated with recombinant erythropoietin. Turk. Neph. Dial. Transpl., 2014, Vol. 23, no. 2, pp. 125-130.

20. Seidl A., Hainzl O., Richter M., Fischer R., Böhm S., Deutel B., Hartinger M., Windisch J., Casadevall N., London G.M., Macdougall I. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm. Res., 2012, Vol. 29, no. 6, pp. 1454-1467.

21. Shin S.K., Ha S.K., Lee KW. Yoo T.H., Yun S.R., Yoon S.H., Kim S.J., Lee S.K., Heo T.H. Application of a bridging ELISA for detection of anti-erythropoietin binding antibodies and a cell-based bioassay for neutralizing antibodies in human sera. J. Pharm. Biomed. Anal., 2010, Vol. 52, no. 2, pp. 289-293.

22. Weeraratne D.K., Kuck A.J., Chirmule N., Mytych D.T. Measurement of anti-erythropoiesis-stimulating agent IgG4 antibody as an indicator of antibody-mediated pure red cell aplasia. Clin. Vaccine Immunol., 2013, Vol. 20, no. 1, pp. 46-51.